Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DRMA | US
0.08
6.40%
Healthcare
Biotechnology
30/06/2024
09/03/2026
1.33
1.25
1.33
1.24
Dermata Therapeutics Inc. a clinical-stage medical dermatology company focuses on identifying developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310 which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. Dermata Therapeutics Inc. was incorporated in 2014 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
63.3%1 month
232.0%3 months
196.0%6 months
152.3%-
-
0.73
-
-
0.58
-
-
-7.86M
2.01M
2.01M
-
-
-
-
-173.01
0.05
4.63
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.22
Range1M
1.18
Range3M
3.55
Rel. volume
0.08
Price X volume
225.15K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CARM | CARM | Biotechnology | 0.044 | 1.83M | 6.02% | n/a | 1044.17% |
| Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.24 | 1.75M | 0.00% | n/a | 6.68% |
| Plus Therapeutics Inc | PSTV | Biotechnology | 0.2952 | 1.74M | 2.25% | n/a | -45.04% |
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.232 | 1.61M | 8.97% | n/a | 0.77% |
| Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.194 | 1.57M | 25.08% | n/a | 5.50% |
| Azitra Inc | AZTR | Biotechnology | 0.203 | 1.55M | 12.53% | 0.01 | 41.86% |
| ERNA | ERNA | Biotechnology | 0.283 | 1.53M | -0.70% | n/a | -577.12% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.2605 | 1.43M | -6.33% | n/a | 268.29% |
| International Stem Cell Corporation | ISCO | Biotechnology | 0.1761 | 1.41M | n/a | 0.00% | |
| XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 0.4599 | 1.38M | -1.88% | n/a | 3.09% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.58 | 0.53 | Par |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.73 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 195.99 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 2.01M | 3.66B | Emerging |